Ultragenyx Pharmaceutical
RARE
220 hedge funds and large institutions have $2.52B invested in Ultragenyx Pharmaceutical in 2023 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 105 increasing their positions, 71 reducing their positions, and 33 closing their positions.
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
48% more repeat investments, than reductions
Existing positions increased: 105 | Existing positions reduced: 71
11% more call options, than puts
Call options by funds: $14M | Put options by funds: $12.7M
0.57% more ownership
Funds ownership: 98.17% → 98.74% (+0.57%)
9% less funds holding
Funds holding: 242 → 220 (-22)
21% less capital invested
Capital invested by funds: $3.21B → $2.52B (-$689M)
64% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$29.7M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$23.1M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$21.2M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$16.6M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$11.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$44.6M |
| 2 |
ClearBridge Investments
New York
|
-$18.6M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$18M |
| 4 |
Two Sigma Investments
New York
|
-$14.4M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$14.1M |
RARE Hedge Fund Activity: Q3 2023 in Review
220 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q3 2023, worth a combined $2.52B — down 21% from $3.21B a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of RARE and 12 opened new positions — a net loss of 21 holders — while 71 trimmed existing stakes and 105 added.
The largest buyer was Avoro Capital Advisors, adding an estimated $29.7M. The largest seller was Capital International Investors, exiting entirely with an estimated $44.6M sold.
- 220 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q3 2023, down from 242 in Q2 2023.
- Funds reported $2.52B of Ultragenyx Pharmaceutical stock for Q3 2023, down 21% quarter-over-quarter.
- 12 funds opened new Ultragenyx Pharmaceutical positions in Q3 2023 and 33 closed out, a net change of -21 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q3 2023 was Avoro Capital Advisors, an estimated $29.7M added.
- The largest Ultragenyx Pharmaceutical seller in Q3 2023 was Capital International Investors, an estimated $44.6M sold.
Based on aggregated 13F filings for Q3 2023.